MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$146.53
+1.29%Next report
Analyst consensus
- Next report date
- Feb 2, 2027
- EPS estimate
- $1.77
- Revenue estimate
- $16.4B
Latest reported
- Last report date
- Oct 29, 2026
- EPS actual
- $2.49
- EPS estimate
- $2.09
- Revenue actual
- $18.1B
- Revenue estimate
- $17.4B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 10
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +21.2%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $165
- PT range
- $140 – $180
- Analysts
- 18
14 Buy4 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 29, 2026 | $2.09 | $2.49 | Beat 19.14% | $18.1B |
| Aug 4, 2026 | -$0.27 | -$0.13 | Beat 51.94% | $16.6B |
| Apr 30, 2026 | -$1.47 | -$1.28 | Beat 12.93% | $16.3B |
| Feb 3, 2026 | $2.02 | $2.04 | Beat 0.99% | $16.4B |
| Oct 30, 2025 | $2.35 | $2.58 | Beat 9.79% | $17.3B |
| Jul 29, 2025 | $2.03 | $2.13 | Beat 4.93% | $15.8B |
| Apr 24, 2025 | $2.13 | $2.22 | Beat 4.23% | $15.5B |
| Feb 4, 2025 | $1.85 | $1.72 | Miss -7.03% | $15.6B |
| Oct 31, 2024 | $1.50 | $1.57 | Beat 4.67% | $16.7B |
| Jul 30, 2024 | $2.15 | $2.28 | Beat 6.05% | $16.1B |
| Apr 25, 2024 | $1.88 | $2.07 | Beat 10.11% | $15.8B |
| Feb 1, 2024 | -$0.09 | $0.03 | Beat 133.33% | $14.6B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 2, 2027